Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Vi-TT

Phase 3Biologic

IInternational Vaccine Institute

Vi-TT is one of 2 biologic programs targeting Vaccine Effectiveness. It is currently in Phase 3.

1

Indications

2

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Vaccine EffectivenessRecruiting

Vaccine EffectivenessPhase 3

Recruiting

Competition

Competitive Landscape

1 competitor in Vaccine Effectiveness

#DrugCompanyPhaseTrials

Vi-TT

IInternational Vaccine Institute

Quadrivalent HPV Vaccine

NNational Institute of Allergy and Infectious Diseases (NIAID)

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Vaccine Effectiveness1 trial

Evaluation of Typhoid Conjugate Vaccine Effectiveness in Ghana

Recruiting·IInternational Vaccine Institute·Phase 4·NCT04852185·23,000 enrolled

Effectiveness1 trial

Effectiveness of a Typhoid Conjugate Vaccine in DRC

Unknown status·IInternational Vaccine Institute·Phase 4·NCT05119426·48,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Vi-TT. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vi-TT compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vi-TT. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — International Vaccine Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: IInternational Vaccine Institute

Related News